Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Hull, UK.
J Thromb Haemost. 2014 Oct;12(10):1733-43. doi: 10.1111/jth.12670. Epub 2014 Sep 18.
Dissecting the signaling events that contribute to platelet activation will increase our understanding of platelet function and aid in the development of new antiplatelet agents. However, high-throughput methodology for the quantitative analysis of platelet signaling events is still lacking.
To develop a high-throughput assay for the analysis of platelet signaling events in whole blood.
We developed a fluorescent barcoding protocol to facilitate multiplexing and enable large-scale signaling profiling in platelets in whole blood. The methodology allowed simultaneous staining and acquisition of 24-96 samples in a single analysis tube with a standard flow cytometer. This approach significantly reduced experimental numbers, data acquisition time, and antibody consumption, while providing automated statistically rich quantitative data on signaling events. Using vasodilator-stimulated phosphoprotein (VASP), an established marker of platelet inhibition and antiplatelet drug therapy, we demonstrated that the assay could detect subtle changes in phosphoVASP-Ser157/239 in response to cAMP-elevating agents of varying potency and known modulators of the cAMP signaling cascade. The assay could be used with washed platelets or whole blood, analyzed immediately or frozen, without any significant change in assay performance. To demonstrate the usefulness of the assay as a drug discovery platform, we examined a prostaglandin screening library. Our screen of 70 prostaglandin derivatives revealed three previously uncharacterized lipids that stimulated phosphorylation of VASP-Ser157. Follow-up analyses demonstrated that these agents elevated intraplatelet cAMP and inhibited collagen-induced platelet aggregation.
This novel method enables rapid, large-scale quantitative signaling profiling and compound screening in human platelets present in whole blood.
解析导致血小板活化的信号事件将增进我们对血小板功能的理解,并有助于开发新的抗血小板药物。然而,高通量方法学仍缺乏用于血小板信号事件的定量分析。
开发一种高通量测定全血中血小板信号事件的方法。
我们开发了一种荧光条码化方案,以促进多重分析,并使全血中的血小板能够进行大规模信号分析。该方法允许在单个分析管中同时对 24-96 个样本进行染色和采集,使用标准流式细胞仪。这种方法大大减少了实验数量、数据采集时间和抗体消耗,同时提供了关于信号事件的自动统计丰富的定量数据。使用已确立的血小板抑制和抗血小板药物治疗标志物环磷酸腺苷(cAMP)-刺激磷酸化蛋白(VASP),我们证明该测定法可以检测到不同效力的 cAMP 升高剂和 cAMP 信号级联的已知调节剂对磷酸化 VASP-Ser157/239 的细微变化。该测定法可用于洗涤后的血小板或全血,可立即分析或冷冻,而不会对测定性能产生任何重大变化。为了证明该测定法作为药物发现平台的有用性,我们对前列腺素筛选文库进行了研究。我们对 70 种前列腺素衍生物的筛选发现了三种以前未表征的刺激 VASP-Ser157 磷酸化的脂质。后续分析表明,这些试剂可升高血小板内 cAMP,并抑制胶原诱导的血小板聚集。
这种新方法能够在富含全血的人血小板中快速、大规模地进行定量信号分析和化合物筛选。